WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 25, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 1, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on February 28, 2023 , the Compensation Committee of the Company’s Board of Directors approved, in
Launched ELAHERE™ (mirvetuximab soravtansine-gynx), the First and Only ADC Approved for Platinum-Resistant Ovarian Cancer in the US; ELAHERE Monotherapy and in Combination with Bevacizumab Included in NCCN Guidelines and Compendium Top-Line Results from Confirmatory MIRASOL Trial Anticipated in Q2
ImmunoGen to Receive a $15 Million Upfront Payment; Eligible to Receive Up to $337 Million in Potential Option Fees and Milestone Payments Plus Tiered Royalties on a Per Target Basis WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 1, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 22, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 15, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Wednesday, March 1, 2023 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 1, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 4, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 29, 2022 , and in connection with the previously announced appointment of Michael J.
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 4, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Michael Vasconcelles , MD, has been appointed Executive Vice President, Research, Development, and
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 28, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , PhD, Senior Vice President and Chief Financial Officer (CFO), is on leave under